Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck’s WINREVAIR Shows Promise in PAH Treatment | Contract Pharma

What are you searching for?

Sign in
Breaking News

Merck’s WINREVAIR Shows Promise in PAH Treatment

Demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Merck has announced positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH). The study met its primary endpoint of reducing the risk of morbidity or mortality events compared to placebo.
 
Based on these results, an independent data monitoring committee recommended early termination of the study, and all participants will be offered access to WINREVAIR through an open-label extension study. Adverse events were balanced between treatment groups.
 
These findings are impressive, set a high evidentiary bar for studies of future candidates developed for the treatment of PAH and support the potential of WINREVAIR to be practice-changing in the management of PAH,” said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.
 
WINREVAIR is already approved in the U.S. and 36 other countries. Merck plans to present the ZENITH results at an upcoming medical meeting and submit them to regulatory authorities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics